BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 31768677)

  • 1. The predictive value of minimal residual disease when facing the inconsistent results detected by real-time quantitative PCR and flow cytometry in NPM1-mutated acute myeloid leukemia.
    Gao MG; Ruan GR; Chang YJ; Liu YR; Qin YZ; Jiang Q; Jiang H; Huang XJ; Zhao XS
    Ann Hematol; 2020 Jan; 99(1):73-82. PubMed ID: 31768677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NPM1-mutated acute myeloid leukemia of monocytic or myeloid origin exhibit distinct immunophenotypes.
    Liu YR; Zhu HH; Ruan GR; Qin YZ; Shi HX; Lai YY; Chang Y; Wang YZ; Lu D; Hao L; Li JL; Li LD; Jiang B; Huang XJ
    Leuk Res; 2013 Jul; 37(7):737-41. PubMed ID: 23601747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group.
    Balsat M; Renneville A; Thomas X; de Botton S; Caillot D; Marceau A; Lemasle E; Marolleau JP; Nibourel O; Berthon C; Raffoux E; Pigneux A; Rodriguez C; Vey N; Cayuela JM; Hayette S; Braun T; Coudé MM; Terre C; Celli-Lebras K; Dombret H; Preudhomme C; Boissel N
    J Clin Oncol; 2017 Jan; 35(2):185-193. PubMed ID: 28056203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison of prognostic significance between multiparameter flow cytometry and real-time quantitative polymerase chain reaction in the detection of minimal residual disease of Philadelphia chromosome-positive acute B lymphocytic leukemia before allogeneic hematopoietic stem cell transplantation].
    Wang XY; Chang YJ; Liu YR; Qin YQ; Xu LP; Wang Y; Zhang XH; Yan CH; Sun YQ; Huang XJ; Zhao XS
    Zhonghua Xue Ye Xue Za Zhi; 2021 Feb; 42(2):116-123. PubMed ID: 33858041
    [No Abstract]   [Full Text] [Related]  

  • 5. [The immunophenotypic and clinical characteristics of NPM1 mutated acute myeloid leukemia patients].
    Liu YR; Chang Y; Ruan GR; Qin YZ; Lai YY; Shi HX; Wang YZ; Li LD; Jiang B; Li JL
    Zhonghua Xue Ye Xue Za Zhi; 2013 Feb; 34(2):98-103. PubMed ID: 23611213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of pre-transplantation minimal residual disease determined by multiparameter flow cytometry on the outcome of AML patients with FLT3-ITD after allogeneic stem cell transplantation.
    Zhao X; Wang Z; Ruan G; Liu Y; Wang Y; Zhang X; Xu L; Huang X; Chang Y
    Ann Hematol; 2018 Jun; 97(6):967-975. PubMed ID: 29423758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Immunophenotypic and clinical characteristic analysis of NPM1 mutated acute myeloid leukemia with a normal karyotype].
    Liu YR; Lai YY; Chang Y; Ruan GR; Qin YZ; Wang YZ; Zhu HH; Shi HX; Jiang B; Jiang H; Jiang Q; Hao L; Li JL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Dec; 21(6):1385-9. PubMed ID: 24370016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved minimal residual disease detection by targeted quantitative polymerase chain reaction in Nucleophosmin 1 type a mutated acute myeloid leukemia.
    Pettersson L; Levéen P; Axler O; Dvorakova D; Juliusson G; Ehinger M
    Genes Chromosomes Cancer; 2016 Oct; 55(10):750-66. PubMed ID: 27191933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation.
    Zhao XS; Liu YR; Zhu HH; Xu LP; Liu DH; Liu KY; Huang XJ
    Ann Hematol; 2012 Feb; 91(2):183-92. PubMed ID: 21710165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.
    Mulé MP; Mannis GN; Wood BL; Radich JP; Hwang J; Ramos NR; Andreadis C; Damon L; Logan AC; Martin TG; Hourigan CS
    Biol Blood Marrow Transplant; 2016 Nov; 22(11):1974-1982. PubMed ID: 27544285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measurable residual disease detected by flow cytometry independently predicts prognoses of NPM1-mutated acute myeloid leukemia.
    Zhang YW; Su L; Tan YH; Lin H; Liu XL; Liu QJ; Sun JN; Zhang M; Du YZ; Song F; Han W; Gao SJ
    Ann Hematol; 2023 Feb; 102(2):337-347. PubMed ID: 36378304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time point-dependent concordance and prognostic significance of flow cytometry and real time quantitative PCR for measurable/minimal residual disease detection in acute myeloid leukemia with t(8;21)(q22;q22.1).
    Shang L; Cai X; Sun W; Cheng Q; Mi Y
    Cytometry B Clin Cytom; 2022 Jan; 102(1):34-43. PubMed ID: 34232569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expression.
    Barragan E; Pajuelo JC; Ballester S; Fuster O; Cervera J; Moscardo F; Senent L; Such E; Sanz MA; Bolufer P
    Clin Chim Acta; 2008 Sep; 395(1-2):120-3. PubMed ID: 18590714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing.
    Salipante SJ; Fromm JR; Shendure J; Wood BL; Wu D
    Mod Pathol; 2014 Nov; 27(11):1438-46. PubMed ID: 24743218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients.
    Bill M; Grimm J; Jentzsch M; Kloss L; Goldmann K; Schulz J; Beinicke S; Häntschel J; Cross M; Vucinic V; Pönisch W; Behre G; Franke GN; Lange T; Niederwieser D; Schwind S
    Ann Hematol; 2018 Oct; 97(10):1757-1765. PubMed ID: 29785446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimal residual disease in acute myelogenous leukemia.
    Cruz NM; Mencia-Trinchant N; Hassane DC; Guzman ML
    Int J Lab Hematol; 2017 May; 39 Suppl 1(Suppl 1):53-60. PubMed ID: 28447422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pattern associated leukemia immunophenotypes and measurable disease detection in acute myeloid leukemia or myelodysplastic syndrome with mutated NPM1.
    Zhou Y; Moon A; Hoyle E; Fromm JR; Chen X; Soma L; Salipante SJ; Wood BL; Wu D
    Cytometry B Clin Cytom; 2019 Jan; 96(1):67-72. PubMed ID: 30417521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minimal/Measurable Residual Disease Monitoring in
    Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flow cytometry in detection of Nucleophosmin 1 mutation in acute myeloid leukemia patients: A reproducible tertiary hospital experience.
    El-Gamal RAE; Hashem AE; Habashy DM; Abou Elwafa MAZ; Boshnak NH
    Int J Lab Hematol; 2021 Feb; 43(1):68-75. PubMed ID: 32856429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimal residual disease detected by multiparameter flow cytometry is complementary to genetics for risk stratification treatment in acute myeloid leukemia with biallelic CEBPA mutations.
    Deng DX; Zhu HH; Liu YR; Chang YJ; Ruan GR; Jia JS; Jiang H; Jiang Q; Zhao XS; Huang XJ
    Leuk Lymphoma; 2019 Sep; 60(9):2181-2189. PubMed ID: 30773106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.